Phase 2 Bladder Clinical Trials
136 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 136 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled9 locationsNCT05796375
Recruiting
Phase 2
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled134 locationsNCT07061964
Recruiting
Phase 2
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Muscle-Invasive Bladder CarcinomaTumor
Leslie Ballas20 enrolled1 locationNCT06417190
Recruiting
Phase 2Phase 3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled493 locationsNCT05987241
Recruiting
Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Recurrent Mucosal MelanomaMucosal MelanomaAnal Melanoma+14 more
National Cancer Institute (NCI)101 enrolled147 locationsNCT05111574
Recruiting
Phase 2
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 1Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Urothelial CarcinomaMuscle Invasive Bladder Cancer
University of California, Irvine23 enrolled1 locationNCT06682728
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 2Phase 3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary IncontinenceOveractive BladderUrologic Diseases+1 more
Northwestern University66 enrolled1 locationNCT05878951
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled124 locationsNCT06770582
Recruiting
Phase 1Phase 2
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Bladder Cancer
Merck Sharp & Dohme LLC55 enrolled14 locationsNCT07232602
Recruiting
Phase 2
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06161532
Recruiting
Phase 2
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 1Phase 2
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Urinary Bladder NeoplasmsBladder Cancer
Merck Sharp & Dohme LLC45 enrolled14 locationsNCT07222488
Recruiting
Phase 1Phase 2
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Cervical CancerMelanomaNon-small Cell Lung Cancer+8 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 1Phase 2
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Urothelial CarcinomaBladder Cancer
Noah Hahn, M.D.55 enrolled12 locationsNCT03317158
Recruiting
Phase 2
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Muscle Invasive Bladder Cancer
Astellas Pharma Global Development, Inc.240 enrolled1 locationNCT07475806